RADX Radiopharm Theranostics (RADX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001949257

Quote by TradingView

Activist 13D

Insider buyers, 180 days

House members buying, 1 year

STOCK Act, US House only, disclosed up to 45 days after the trade

Funds added, last quarter

13F, latest reported quarter

What the filings say about RADX

Activist stakes (13D), 180 days

1 filing

Largest: 20.9% of the class

Radiopharm Theranostics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Radiopharm Theranostics Ltd in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider

Filed

Value

Since filing

no insider purchases or sales on record

0 transactions on record

See all insider buying · insider selling

Seven facts, ranked against the sector · Rank is not a forecast

Insiders

no insider buys or sells on file

Congress

no House purchase disclosed in the last 12 months

Funds

4 funds bought in last quarter

below 97% of Pharma & Biotech

Revenue

no revenue reported in any filing

Margin

no margin: no revenue reported

Buybacks

no share repurchases reported

Short interest

1.2% of the float short (float per yahoo 2026-10-27) · 2.4 days to cover · settled 2026-10-15

the lowest in Pharma & Biotech

The situation: each line is one rule over one dataset

Lantheus Omega, LLC disclosed a 5%+ stake (20.9%) in the last six months.

What changed in the last 30 days

Nothing new filed in the last 30 days

Watch RADX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns RADX: institutional holders (13F)

13F holdings, latest reported quarter

Stonepine Capital Management, LLC

153,000,000 sh

$1.5M

HSBC HOLDINGS PLC

62,188 sh

$253.7K

Regal Partners Ltd

40,138 sh

$168.2K

PNC Financial Services Group, Inc.

20,000 sh

$83.8K

UBS Group AG

1,507 sh

$6.3K

Congress trades in RADX

No Congress trades reported

No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive

Lantheus Omega, LLC

Activist 13D · 2026-09-04

20.9%

Lantheus Medical Imaging, Inc.

Activist 13D · 2026-09-04

20.9%

Lantheus Holdings, Inc.

Activist 13D · 2026-09-04

20.9%

RADX planned insider sales (Form 144)

No planned-sale notices

No insider has filed to sell. Watch this after a run-up.

Clinical pipeline

7 registered trials, 7 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.

Phase 1

2 active

Phase 2

1 active

Early Phase 1

2 active

Multi-phase

2 active

What changed recently

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Othe

2026-09-15 · Completion moved 2026-08 → 2026-09

Phase 1

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Othe

2026-09-15 · Recruiting → Active Not Recruiting

Phase 1

Matched by sponsor name. Trials run under a subsidiary's own name are not included.

Live price

Daily candles from TradingView, under their licence. No filings marked.

Show the live price chart

Why this name is on the desk

An activist crossed the 5% line with declared intent.

The record shows 4 funds added last quarter. Each figure is a federal filing, dated the day it went public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector by SEC SIC code

UTHR CPIX MRNA REGN LLY ALNY MDGL CITR DNA VRTX NUVL TWST

RADX financials

Fundamentals

Annual figures from XBRL filings. Pick a past date to see them as known then.

	2025-06	2024-06	2023-06
Gross profit	$39.3K	$299.2K	$292.4K
Net income	-$38.3M	-$47.9M	-$34.6M

SEC XBRL, fiscal years, as known on 2026-10-28

RADX Stock Sonar score 2/7 axes

Find similar shapes Compare

Institutional and government

Inputs

Funds adding, latest quarter4 · 3 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters

Risk and compliance

Inputs

Short interest, % of float+1.2% · 78 pct, sector of 816
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)

5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents

Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RADX filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 20.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing

Insider buying Insider selling Congress stock trades Activist 13D stakes Form 144 planned sales CEO pay vs performance All companies